company background image
300357 logo

Zhejiang Wolwo Bio-Pharmaceutical SZSE:300357 Stock Report

Last Price

CN¥18.82

Market Cap

CN¥9.9b

7D

-1.5%

1Y

-46.8%

Updated

23 Jul, 2024

Data

Company Financials +

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

SZSE:300357 Stock Report

Market Cap: CN¥9.9b

300357 Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally.

300357 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zhejiang Wolwo Bio-Pharmaceutical
Historical stock prices
Current Share PriceCN¥18.82
52 Week HighCN¥41.94
52 Week LowCN¥18.44
Beta0.55
11 Month Change-8.60%
3 Month Change-19.09%
1 Year Change-46.76%
33 Year Change-69.94%
5 Year Change-41.26%
Change since IPO234.69%

Recent News & Updates

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Jun 30
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

May 27
Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

Recent updates

Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Jun 30
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185

Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

May 27
Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking

Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

May 07
Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)

Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Mar 22
Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?

Shareholder Returns

300357CN PharmaceuticalsCN Market
7D-1.5%3.0%0.5%
1Y-46.8%-13.4%-16.6%

Return vs Industry: 300357 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.

Return vs Market: 300357 underperformed the CN Market which returned -16.6% over the past year.

Price Volatility

Is 300357's price volatile compared to industry and market?
300357 volatility
300357 Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.1%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 300357's share price has been volatile over the past 3 months.

Volatility Over Time: 300357's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20021,709Gengxi Huwww.wolwobiotech.com

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a farinae farinae drops; Changhao, an artemisia annua pollen allergen sublingual drops; Changdian, a dust mite skin prick diagnostic kits; and Changdian II, a house dust mite skin pricking diagnostic kits. It also involved in the research and development of stem cells and medical artificial intelligence solutions.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Fundamentals Summary

How do Zhejiang Wolwo Bio-Pharmaceutical's earnings and revenue compare to its market cap?
300357 fundamental statistics
Market capCN¥9.85b
Earnings (TTM)CN¥316.91m
Revenue (TTM)CN¥881.30m

31.1x

P/E Ratio

11.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300357 income statement (TTM)
RevenueCN¥881.30m
Cost of RevenueCN¥40.98m
Gross ProfitCN¥840.32m
Other ExpensesCN¥523.40m
EarningsCN¥316.91m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 23, 2024

Earnings per share (EPS)0.61
Gross Margin95.35%
Net Profit Margin35.96%
Debt/Equity Ratio2.1%

How did 300357 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

31%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.